ArticleAmerican heart journal plus : cardiology research and practice2026
ACOT1-specific expression modulates metabolic reprogramming in diabetic cardiomyopathy: The role of SREBP1c lactylation in CD36-mediated lipotoxicity.
Article in American heart journal plus : cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Diabetic cardiomyopathy (DCM) is characterized by metabolic dysfunction and lipotoxicity. The roles of acyl-CoA thioesterase 1 (ACOT1) and the novel post-translational modification lactylation in its pathogenesis remain unclear. This study aimed to investigate the stage-specific function of ACOT1 and the mechanism by which lactylation of SREBP1c regulates lipid metabolism in DCM. Methods: Key genes were screened via bioinformatic analysis. ACOT1 was functionally assessed in early and decompensated DCM mouse models using gain- and loss-of-function strategies, evaluated by echocardiography and hemodynamics. SREBP1c lactylation was identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and validated via site-directed mutagenesis. Results: ACOT1 exhibited a biphasic expression pattern: protective upregulation in early DCM improved cardiac function and attenuated oxidative stress, whereas its downregulation in decompensated DCM exacerbated remodeling and dysfunction. Mechanistically, ACOT1 physically interacted with SREBP1c and facilitated its lactylation under high-lactate conditions. This modification was essential for SREBP1c transcriptional activity, driving its nuclear translocation and subsequent upregulation of the fatty acid transporter CD36. The enhanced CD36-mediated uptake led to free fatty acid accumulation, aggravating myocardial lipotoxicity and DCM progression. Conclusion: This study reveals a dual-stage regulatory role of ACOT1 in DCM and identifies a novel ACOT1-SREBP1c(lactylation)-CD36 axis linking metabolic reprogramming to lipotoxic injury. These findings establish lactylation as a key regulatory mechanism in diabetic heart metabolism and propose ACOT1 and SREBP1c lactylation as potential therapeutic targets for mitigating myocardial lipotoxicity in DCM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.